Search Results - "Strawderman, M H"

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684 by Kirkwood, J M, Strawderman, M H, Ernstoff, M S, Smith, T J, Borden, E C, Blum, R H

“…Interferon alfa-2b (IFN alpha-2b) exhibits antitumor activity in metastatic melanoma and on this basis has been evaluated as an adjuvant therapy following…”
Get more information

Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy by Sartor, C I, Strawderman, M H, Lin, X H, Kish, K E, McLaughlin, P W, Sandler, H M

“…A rising prostate specific antigen (PSA) following treatment for adenocarcinoma of the prostate indicates eventual clinical failure, but the rate of rise can…”
Get more information

Microscopic extracapsular extension in the axilla: is this an indication for axillary radiotherapy? by Pierce, L J, Oberman, H A, Strawderman, M H, Lichter, A S

“…Although the axilla is often treated with radiotherapy (RT) postoperatively when microscopic extracapsular extension (ECE) of lymph nodal metastases is…”
Get more information

Conservative surgery and radiotherapy for early-stage breast cancer using a lung density correction: the University of Michigan experience by Pierce, L J, Strawderman, M H, Douglas, K R, Lichter, A S

“…Although an abundance of reports detail the successful use of definitive radiotherapy of the breast in the treatment in Stage I or II breast cancer, little…”
Get more information

Interferon Alfa-2b Adjuvant Therapy of High-Risk Resected Cutaneous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684 by Kirkwood, J M, Strawderman, M H, Ernstoff, M S, Smith, T J, Borden, E C, Blum, R H

“…Interferon alfa-2b (IFN alpha-2b) exhibits antitumor activity in metastatic melanoma and on this basis has been evaluated as an adjuvant therapy following…”
Get full text

Conventional dose melphalan is inactive in metastatic melanoma: results of an Eastern Cooperative Oncology Group Study (E1687) by Hochster, H, Strawderman, M H, Harris, J E, Atkins, M B, Oken, M, Skeel, R T, Jubelirer, S J, Parkinson, D

“…Despite reports that i.v. melphalan is active in the settings of conditioning regimens utilizing high-dose chemotherapy for autologous bone marrow…”
Get more information